Search

Syndax Pharmaceuticals Inc

Închisă

SectorSănătate

16.98 0.95

Rezumat

Modificarea prețului

24h

Curent

Minim

16.37

Maxim

17.28

Indicatori cheie

By Trading Economics

Venit

-6.7M

-49M

Vânzări

7.9M

73M

EPS

-0.55

Marjă de profit

-67.817

Angajați

298

EBITDA

-5.9M

-37M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+119.22% upside

Dividende

By Acuity

Următoarele câștiguri

2 nov. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

-125M

1.6B

Deschiderea anterioară

16.03

Închiderea anterioară

16.98

Sentimentul știrilor

By Acuity

77%

23%

302 / 340 Clasament în Healthcare

Syndax Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

7 oct. 2026, 23:20 UTC

Syndax Pharmaceuticals Inc gained modestly in after-market hours, though it remains below its 20-day moving average and near the lower end of its one-month range.

6 oct. 2026, 20:07 UTC

Syndax Pharmaceuticals Inc shares fell sharply, hitting a low of over 5% earlier, and remain below the 20-day moving average.

2 oct. 2026, 19:15 UTC

Syndax Pharmaceuticals Inc shares fell sharply, facing significant downward pressure and trading notably below its 20-day moving average amid broader biotechnology sector weakness.

1 oct. 2026, 20:07 UTC

Social Media

Shares of Syndax Pharmaceuticals fell despite positive analyst ratings from H.C. Wainwright and Jefferies, remaining below the 20-day moving average.

30 sept. 2026, 20:07 UTC

Syndax Pharmaceuticals Inc is experiencing gains in Wednesday's trading session, rebounding significantly after an early dip and achieving a notable cumulative return since Tuesday.

29 sept. 2026, 23:30 UTC

Syndax Pharmaceuticals Inc is rising in after-market trading, advancing from a low point post-market close and currently near the midpoint of its one-month trading range.

28 sept. 2026, 19:16 UTC

News

Syndax Pharmaceuticals Inc. shares fell, remaining below the 20-day moving average despite being rated a "Strong Buy" following FDA approval for Revuforj.

25 sept. 2026, 19:46 UTC

News
Social Media

Syndax Pharmaceuticals reaffirms over $2 billion in U.S. peak sales for Revuforj after SAVE trial results show an 88% overall response rate, driving shares higher.

24 sept. 2026, 20:12 UTC

Syndax Pharmaceuticals Inc is trading higher in after-market hours, maintaining a steady position since Thursday's close, despite being below its 20-day moving average.

23 sept. 2026, 20:07 UTC

Syndax Pharmaceuticals Inc shares fell sharply, reaching their lowest point around midday and remaining below the 20-day moving average after a significant decline from Tuesday's close.

22 sept. 2026, 19:45 UTC

Syndax Pharmaceuticals Inc is trading modestly higher, though the price remains below its 20-day moving average and near the lower end of its one-month range.

21 sept. 2026, 21:11 UTC

Syndax Pharmaceuticals Inc is advancing in after-market trading, reflecting notable upward movement since Monday's close, despite remaining below its 20-day moving average.

17 sept. 2026, 20:07 UTC

Syndax Pharmaceuticals Inc is trading higher, having seen a steady increase, despite being below its 20-day moving average and near the lower end of its one-month range.

16 sept. 2026, 20:06 UTC

Macro Event

Syndax Pharmaceuticals Inc shares fell sharply, driven by heightened volatility in the healthcare sector following the Federal Reserve's recent 25 basis point interest rate hike.

15 sept. 2026, 20:07 UTC

Syndax Pharmaceuticals Inc shares are lower amid a broader market decline following a sharp drop in the NY Empire State Manufacturing Index for September.

11 sept. 2026, 19:36 UTC

News

Syndax Pharmaceuticals is lower today, continuing a downward trend amid heightened market volatility following the August Consumer Price Index release.

10 sept. 2026, 20:03 UTC

Syndax Pharmaceuticals Inc shares are lower today, continuing a decline since Wednesday's close, with no specific news identified to explain the movement.

8 sept. 2026, 20:07 UTC

News

Syndax Pharmaceuticals is lower today amid broader market weakness and speculation about a Federal Reserve interest rate hike following strong labor data.

2 sept. 2026, 20:08 UTC

Syndax Pharmaceuticals Inc shares are higher today, despite earlier pulling back from a session high amid broader market volatility and slower job growth indicators.

1 sept. 2026, 20:09 UTC

News

Syndax Pharmaceuticals shares are higher as the company announces participation in two investor conferences to boost visibility for its cancer therapies.

25 aug. 2026, 19:26 UTC

Syndax Pharmaceuticals Inc shares are higher today, maintaining gains since Monday. The stock remains above the 20-day moving average amid declining yields.

24 aug. 2026, 19:51 UTC

Syndax Pharmaceuticals Inc is trading lower, breaking a trend of higher closes. Broader market sentiment is impacted by concerns over U.S.-Iran relations and oil supply disruptions.

21 aug. 2026, 19:21 UTC

Syndax Pharmaceuticals shares are lower today, breaking a trend of higher closes since Thursday. The broader market faces volatility amid rising crude oil prices.

20 aug. 2026, 20:02 UTC

Correlated Moves

Syndax trades lower amid decline in SPDR S&P Biotech ETF.

19 aug. 2026, 19:27 UTC

Correlated Moves

SNDX higher today, supported by strong biotechnology sector performance.

18 aug. 2026, 19:56 UTC

Syndax Pharmaceuticals is trading higher today, despite pulling back from earlier session gains. The stock remains positioned near the lower end of its one-month range.

17 aug. 2026, 19:36 UTC

Correlated Moves

Shares higher today as iShares Biotechnology ETF also gains.

14 aug. 2026, 19:26 UTC

Syndax Pharmaceuticals Inc shares are trading higher during Friday's session, reflecting positive market sentiment despite broader concerns over a decline in U.S. retail sales.

12 aug. 2026, 19:31 UTC

Syndax Pharmaceuticals shares are lower, reversing a recent trend of gains. No specific news was identified to explain the decline.

11 aug. 2026, 19:26 UTC

News

SNDX trades lower after JPMorgan cuts price target to $40.00.

Comparație

Modificare preț

Syndax Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

119.22% sus

Prognoză pe 12 luni

Medie 37.333 USD  119.22%

Maxim 57 USD

Minim 26 USD

În baza a 10 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruSyndax Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

10 ratings

10

Cumpărare

0

Păstrare

0

Vânzare

Sentiment

By Acuity

302 / 340 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.